Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
April 2, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
a man holding a ball in his right hand

Photo by julien Tromeur on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • 94% of physicians have already adopted AI tools or are interested in doing so, with more than half now using AI in their practice — up from 47% in early 2025 to 63% by late 2025 and early 2026, per a Doximity survey of over 3,000 doctors
  • More than 70% of physicians cited accuracy and reliability as a top barrier to broader AI adoption, and nearly half pointed to legal and regulatory uncertainty
  • Three-quarters of physicians who had already adopted AI reported reduced administrative burden and better job satisfaction; nearly half said AI improved their capacity to take on new patients
  • Only 8% of physicians said their organization’s AI decision-making process is clear and well-understood — while about half said it is “still evolving” — highlighting a significant governance gap

What Happened?

A new survey by Doximity, the medical professional network and technology company, finds that AI adoption among physicians is accelerating rapidly — but concerns about accuracy and unclear organizational governance are slowing full integration. Of more than 3,000 physicians surveyed across two periods, 94% said they had already adopted AI tools or are interested in doing so, with just 5% saying they weren’t interested. Adoption has surged: 47% reported using AI during the first survey period in early 2025; by the second period from November through January, that figure had risen to 63%. The most common use cases were literature search and AI-powered scribing tools that record patient conversations and draft clinical documentation. Despite the rapid adoption, more than 70% cited accuracy and reliability as a top barrier, and nearly half flagged legal and regulatory uncertainty as a concern.

Why It Matters?

The Doximity survey captures a pivotal inflection point in healthcare AI: the technology has crossed from “early adopter” territory to mainstream clinical interest in under three years, but the infrastructure — governance, regulation, and trust — hasn’t kept pace. The gap is most visible in organizational readiness: only 8% of physicians said their organization’s AI policies and guidelines are clear, while about half said the process is “still evolving.” That ambiguity creates liability exposure for health systems and confusion for individual clinicians trying to deploy AI responsibly. For healthcare investors, the survey underscores both the size of the opportunity and the friction that remains. The AI tools generating the most physician enthusiasm — scribing, literature search, administrative automation — are also among the lower-risk applications, suggesting adoption will continue to build from the bottom up before moving into higher-stakes clinical decision support.

What’s Next?

The governance gap is the most actionable finding for health systems: with 92% of physicians either using or interested in AI, the question is no longer whether to deploy these tools but how to deploy them safely and with clear institutional policies. Organizations that move quickly to establish clear guidelines, training, and accountability frameworks will be better positioned to capture the productivity and retention benefits AI can deliver — and to avoid the legal and regulatory exposure that currently concerns nearly half of physicians. For AI vendors, the survey signals strong underlying demand but also the need to invest in accuracy validation and explainability, given that reliability concerns are the top barrier. Regulatory clarity from the FDA and CMS on AI-powered clinical tools will be a critical catalyst for the next phase of adoption.

Source: Healthcare Dive

Previous Post

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

Next Post

Trump Threatens to Escalate Iran War — But Says End Is ‘Very Close’

Recommended For You

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
1 day ago
Auto Draft

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
2 days ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
6 days ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
1 week ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
1 week ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more

Generic Ozempic Wave Could Redraw the Global GLP-1 Market

by Team Lumida
2 weeks ago
Generic Ozempic Wave Could Redraw the Global GLP-1 Market

Key Takeaways Powered by lumidawealth.com India is set to become the first major market to see a large-scale rollout of generic semaglutide, with at least a dozen major drugmakers...

Read more

Yoga Is the Longevity Habit Most People Underestimate

by Team Lumida
2 weeks ago
woman in black tank top and black pants bending her body on floor

Key takeaways Powered by lumidawealth.com Improves flexibility, balance, and joint health, reducing injury risk with age. Lowers stress and cortisol, supporting heart and metabolic health. Enhances nervous system regulation,...

Read more

Grip Strength Is a Longevity Biomarker

by Team Lumida
2 weeks ago
a person lifting a barbell in a gym

Key takeaways Powered by lumidawealth.com Lower grip strength is linked to higher mortality risk. It correlates with cardiovascular health, muscle mass, and frailty. Declining grip strength often signals system-wide...

Read more

Most “Longevity Drugs” Don’t Work the Way You Think

by Team Lumida
2 weeks ago
diagram

Key takeaways Powered by lumidawealth.com Most longevity drugs improve markers, not actual lifespan. Human evidence is weak for many popular compounds. Drug benefits are context-dependent — not universal. Lifestyle...

Read more

Walking After Meals Is a Simple Hack for Blood Sugar Control

by Team Lumida
2 weeks ago
woman walking on pathway during daytime

Key takeaways Powered by lumidawealth.com Just 10–15 minutes of walking after meals can lower post-meal blood sugar spikes. Light activity helps muscles absorb glucose without needing as much insulin....

Read more
Next Post
House Rebuke of Canada Tariffs Exposes Political Risk Around Trump’s Trade Agenda

Trump Threatens to Escalate Iran War — But Says End Is 'Very Close'

Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

Supreme Court Signals It Will Strike Down Trump's Birthright Citizenship Order

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China Stimulus: Enough to Sway Markets?

Google Parent Alphabet in Talks to Acquire Cybersecurity Firm Wiz for $30 Billion

March 18, 2025
Apple Integrates ChatGPT Without Spending a Dime

Apple Joins OpenAI: Phil Schiller to Observe OpenAI Board

July 3, 2024
red and blue light streaks

Global Trade Faces Another Volatile Year as Tariffs, Supply Chains, and Legal Risks Collide in 2026

December 24, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018